Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
The Journal of Pathology. Clinical Research
|
September 9, 2020
Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore
Pamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, et al.
Gut
|
February 12, 2020
Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients
Julie Rodriguez, Sophie Hiel, Audrey M Neyrinck, et al.
JCI Insight
|
April 8, 2024
Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance
Nadejda Bozadjieva-Kramer, Jae Hoon Shin, Ziru Li, et al.
Translational Gastroenterology and Hepatology
|
February 13, 2025
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis
Adrienne Lejeune, Peter Stärkel, Alexandre Louvet, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
May 1, 2023
Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia
Adeline Dolly, Sarah A Pötgens, Morgane M Thibaut, et al.
Brain, Behavior, and Immunity
|
January 30, 2021
Prebiotic effect on mood in obese patients is determined by the initial gut microbiota composition: A randomized, controlled trial
Quentin Leyrolle, Renata Cserjesi, Maria D G H Mulders, et al.
Clinical Nutrition (Edinburgh, Scotland)
|
October 7, 2020
Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients
Quentin Leyrolle, Renata Cserjesi, Maria D G H Mulders, et al.
Clinical Nutrition (Edinburgh, Scotland)
|
April 29, 2020
Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial
Sophie Hiel, Marco A Gianfrancesco, Julie Rodriguez, et al.
The New England Journal of Medicine
|
October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
The Journal of Pathology. Clinical Research
|
September 9, 2020
Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore
Pamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, et al.
Gut
|
February 12, 2020
Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients
Julie Rodriguez, Sophie Hiel, Audrey M Neyrinck, et al.
JCI Insight
|
April 8, 2024
Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance
Nadejda Bozadjieva-Kramer, Jae Hoon Shin, Ziru Li, et al.
Translational Gastroenterology and Hepatology
|
February 13, 2025
Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis
Adrienne Lejeune, Peter Stärkel, Alexandre Louvet, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
May 1, 2023
Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia
Adeline Dolly, Sarah A Pötgens, Morgane M Thibaut, et al.
Brain, Behavior, and Immunity
|
January 30, 2021
Prebiotic effect on mood in obese patients is determined by the initial gut microbiota composition: A randomized, controlled trial
Quentin Leyrolle, Renata Cserjesi, Maria D G H Mulders, et al.
Clinical Nutrition (Edinburgh, Scotland)
|
October 7, 2020
Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients
Quentin Leyrolle, Renata Cserjesi, Maria D G H Mulders, et al.
Clinical Nutrition (Edinburgh, Scotland)
|
April 29, 2020
Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial
Sophie Hiel, Marco A Gianfrancesco, Julie Rodriguez, et al.
The New England Journal of Medicine
|
October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Page
of 8